THE LONGEST CLINICAL TRIAL YET OF BLOCKBUSTER WEIGHT LOSS DRUG WEGOVY REVEALS SIGNIFICANT SIDE EFFECTS

Summary from the TLDR newsletter

A study on semaglutide that assessed around 17,600 adults in multiple countries from 2018 to 2021 found that participants lost an average of 10% of their body weight. 17% of the participants left the trial due to side effects that included nausea, diarrhea, vomiting, and constipation, which were most often felt during the initial months of treatment. The drug reduced major cardiovascular events by 20% - this effect was evident even in participants who didn't lose weight. The study suggests the drug could be potentially used for other purposes and could help make a case for more widespread insurance.